| Literature DB >> 28685064 |
Harumichi Itoh1, Shimpei Nishikawa1, Tomoya Haraguchi1, Yu Arikawa1, Masato Hiyama2, Toshie Iseri3, Yoshiki Itoh3, Munekazu Nakaichi3, Yasuho Taura2, Kenji Tani2, Kazuhito Itamoto1.
Abstract
The majority of cases of chemotherapy for hepatocellular carcinoma (HCC) are not effective in human or veterinary medicine due to resistance against anticancer agents. In human medicine, hepatocellular carcinoma stem cells (HCSCs) were recently identified as cytokeratin 19 (CK19)-, cluster of differentiation (CD)-44-, and CD133-positive. However, there are few previous reports regarding canine HCSC (cHCSC). Additionally, to the best of our knowledge, the chemoresistance against anticancer agents of these cHCSCs has not been investigated. In the present study staining of cHCSCs was performed with rhodamine 123, a low-toxicity fluorescent dye for mitochondria, by flow cytometry. There were two subpopulations in the HCC cell line defined by their higher (RhoHi) and lower (RhoLo) fluorescence intensity of rhodamine 123. The RhoHi subpopulation demonstrated a higher Nanog gene expression, sphere-forming ability, and chemoresistance against gemcitabine. However, there was no significant difference between RhoHi and RhoLo regarding the proliferation rate and chemoresistance against mitoxantrone and doxorubicin. The present results indicate that the expression of rhodamine 123 identifies different stem cell subpopulations in a canine HCC cell line.Entities:
Keywords: cancer stem cell; canine hepatocellular carcinoma; rhodamine 123; subpopulation
Year: 2017 PMID: 28685064 PMCID: PMC5492824 DOI: 10.3892/br.2017.925
Source DB: PubMed Journal: Biomed Rep ISSN: 2049-9434